AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals has filed the CRISIL Monitoring Agency Report on use of its IPO proceeds for the quarter ended March 31, 2025. The IPO (held July 30 – August 1, 2024) raised Rs 6,800 million in gross proceeds, with net proceeds of Rs 6,373.70 million after issue expenses. As of March 31, 2025, Rs 6,292.30 million has been deployed: debt repayment of the company (Rs 1,599.10 million) and subsidiaries (Rs 2,270.90 million), working capital (Rs 550 million, fully utilized this quarter), and general corporate purposes (Rs 1,675 million) are all fully done. For the inorganic growth/acquisitions object, only Rs 197.30 million of the planned Rs 278.70 million has been used — a delay is acknowledged, with the company citing the prospectus provision allowing carry-forward to the next fiscal year. Unutilized proceeds of Rs 81.40 million sit in ICICI Bank fixed deposits, and Rs 195.91 million remains in the public offer account for issue expenses. No deviation from the stated objects was reported.
The report confirms IPO funds have been largely used as promised, with no diversion or material deviation — a positive compliance signal for shareholders. The delay in the acquisitions object is minor and disclosed, so it is unlikely to weigh on the stock, though investors should watch whether the remaining Rs 81.40 million for the Ambernath R&D land deal is deployed in FY26.